Here's what Goldman Sachs is saying about the Core Lithium share price now

Goldman Sachs is bearish on this lithium share…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Core Lithium Ltd (ASX: CXO) share price has started 2023 in a positive fashion.

As you can see below, the lithium developer's shares have rebounded strongly from significant weakness in December.

This leaves Core Lithium's shares trading almost 17% higher year to date at $1.19.

A woman holds her hands to her face in shock and fear with a worried expression on her face.

Image source: Getty Images

Where next for the Core Lithium share price?

Unfortunately, the team at Goldman Sachs believes the company's shares are heading lower again from here.

According to a note from this morning, the broker has reiterated its sell rating and 95 cents price target.

Based on the current Core Lithium share price, this suggests that the ASX 200 lithium share could tumble 20% over the next 12 months.

What did the broker say?

The main reason for Goldman's bearish sentiment is the company's valuation. The broker explained:

CXO looks relatively expensive vs. peers trading at 1.4x NAV (peer average ~1.0x; on GSe LT US$1,000/t spodumene), pricing in ~US$2,050/t (peer average ~US$1,100/t) or implying current pricing persists for ~1.5 years (peer average <1 year), while also having the lowest average operating FCF/t LCE — essentially embedding significant resource upside and capacity expansion/life extension ahead of fundamentals, in our view.

Goldman also believes production risks are not appreciated by the market. It adds:

We see production risk as the Finniss project moves through ramp up on project complexity (moving between different open pits and underground configurations), and the required exploration/resource upside to support capacity expansion/life extension currently priced into the stock looks significant.

Overall, the broker feels investors should be skipping Core Lithium and buying rival Allkem Ltd (ASX: AKE) right now. As covered here, Goldman Sachs has a buy rating and $15.20 price target on the latter.

Motley Fool contributor James Mickleboro has positions in Allkem. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Two work colleagues looking at a laptop and discussing something.
Broker Notes

Three ASX shares set to rise up to 47% – Expert

These ASX shares were earnings results winners.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

This ASX 200 gold stock could be a top buy after a 'transformational' year

Bell Potter is bullish on this name. Let's find out why.

Read more »

Woman analysing data.
Broker Notes

What is Bell Potter saying about EOS shares after its results?

The broker remains bullish on this rapidly growing stock.

Read more »

Happy man on a supermarket trolley full of groceries with a woman standing beside him.
Broker Notes

Are Coles shares a buy after its results?

Bell Potter has given its view on the supermarket giant.

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

3 ASX shares Macquarie says will return 23% to 49%

These shares are well-positioned for a strong year.

Read more »

Woman and man at work looking at data on a tablet at work.
Broker Notes

Buy, hold, sell: Judo Capital, Healius, BHP shares

Morgans has issued new notes on several stocks including BHP, which hit a new record today.

Read more »

Woman with her kitten on a laptop in her home office.
Broker Notes

Buy, hold, sell: Bendigo and Adelaide Bank, PLS, EOS shares

These three ASX shares posted their FY26 results this week. Find out what brokers tip next.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Bell Potter says this ASX biotech could nearly double in value

The US market is starting to open up for this company.

Read more »